JPWO2020115048A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020115048A5 JPWO2020115048A5 JP2021552785A JP2021552785A JPWO2020115048A5 JP WO2020115048 A5 JPWO2020115048 A5 JP WO2020115048A5 JP 2021552785 A JP2021552785 A JP 2021552785A JP 2021552785 A JP2021552785 A JP 2021552785A JP WO2020115048 A5 JPWO2020115048 A5 JP WO2020115048A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- gip
- peptide analogue
- gip peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 235000001014 amino acid Nutrition 0.000 claims 19
- 125000000539 amino acid group Chemical group 0.000 claims 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims 12
- 229930195729 fatty acid Natural products 0.000 claims 12
- 239000000194 fatty acid Substances 0.000 claims 12
- 150000004665 fatty acids Chemical class 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 7
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 claims 5
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 claims 5
- 108010011459 Exenatide Proteins 0.000 claims 4
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 229960001519 exenatide Drugs 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- -1 GP Chemical compound 0.000 claims 2
- YONJPLIBVIENNO-LAEOZQHASA-N (2s)-2-amino-5-[[(2r)-3-[(1s)-1-amino-1-carboxy-2-methylpropan-2-yl]sulfanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](N)C(C)(C)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YONJPLIBVIENNO-LAEOZQHASA-N 0.000 claims 2
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108700034543 penicillamine-glutathione mixed disulfide Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 claims 1
- RIFRYROLBMMDGQ-UHFFFAOYSA-N 5-amino-2-(2-aminoethyl)-3-oxohexanoic acid Chemical compound NC(CC(=O)C(C(=O)O)CCN)C RIFRYROLBMMDGQ-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 244000137850 Marrubium vulgare Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 150000001371 alpha-amino acids Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 230000004136 fatty acid synthesis Effects 0.000 claims 1
- 235000021588 free fatty acids Nutrition 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004190 glucose uptake Effects 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18209896 | 2018-12-03 | ||
| EP18209896.2 | 2018-12-03 | ||
| EP19176739.1 | 2019-05-27 | ||
| EP19176739 | 2019-05-27 | ||
| PCT/EP2019/083506 WO2020115048A1 (en) | 2018-12-03 | 2019-12-03 | Modified gip peptide analogues |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509568A JP2022509568A (ja) | 2022-01-20 |
| JPWO2020115048A5 true JPWO2020115048A5 (enExample) | 2022-12-07 |
| JP7605747B2 JP7605747B2 (ja) | 2024-12-24 |
Family
ID=68731999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552785A Active JP7605747B2 (ja) | 2018-12-03 | 2019-12-03 | 修飾されたｇｉｐペプチド類似体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12297250B2 (enExample) |
| EP (2) | EP3891174A1 (enExample) |
| JP (1) | JP7605747B2 (enExample) |
| KR (2) | KR102906485B1 (enExample) |
| CN (3) | CN121449720A (enExample) |
| AU (2) | AU2019391300B2 (enExample) |
| BR (1) | BR112021010447A2 (enExample) |
| CA (1) | CA3121043A1 (enExample) |
| IL (1) | IL283385A (enExample) |
| MX (1) | MX2021006505A (enExample) |
| SG (1) | SG11202105586YA (enExample) |
| WO (2) | WO2020115048A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7788376B2 (ja) * | 2019-12-03 | 2025-12-18 | アンタグ セラピューティクス エーピーエス | 最適化されたｇｉｐペプチド類縁体 |
| WO2022007809A1 (zh) * | 2020-07-06 | 2022-01-13 | 鸿绪生物医药科技（北京）有限公司 | 新型多肽制剂及其治疗用途 |
| AU2021304762B2 (en) * | 2020-07-06 | 2024-05-02 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic use thereof |
| EP4281464A4 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| KR20240021212A (ko) * | 2021-06-10 | 2024-02-16 | 안타그 테라퓨틱스 에이피에스 | 비만 및 비만-관련 장애의 치료 |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| WO2023139106A2 (en) | 2022-01-18 | 2023-07-27 | Novo Nordisk A/S | Long-acting gipr antagonists |
| CN119522233A (zh) * | 2022-07-13 | 2025-02-25 | 杭州中美华东制药有限公司 | Glp-1/gip双激动剂及其制备方法和用途 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| JP2026507088A (ja) * | 2023-02-24 | 2026-02-27 | アイピー２アイピーオー イノベ－ションズ リミテッド | 化合物 |
| GB202302686D0 (en) * | 2023-02-24 | 2023-04-12 | Imperial College Innovations Ltd | Novel compounds |
| EP4687947A1 (en) * | 2023-04-05 | 2026-02-11 | Antag Therapeutics ApS | Gip activity modulators and orthostatic intolerance |
| TW202529796A (zh) * | 2023-11-22 | 2025-08-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1r/gipr雙標靶激動劑在製備動物藥的用途 |
| WO2025154021A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154020A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025176999A2 (en) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Novel compounds |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US5745335A (en) | 1996-06-27 | 1998-04-28 | Gennum Corporation | Multi-layer film capacitor structures and method |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| JP3270761B2 (ja) | 1998-01-30 | 2002-04-02 | ノボ ノルディスク アクティーゼルスカブ | 注射器 |
| AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| ATE269103T1 (de) | 1998-03-13 | 2004-07-15 | Novo Nordisk As | Stabilisierte wässerige glukagonlösungen enthaltend detergenzien |
| AU6294899A (en) | 1998-10-07 | 2000-04-26 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| CN1495198A (zh) | 1998-12-07 | 2004-05-12 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 胰高血糖素样肽-1的类似物 |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| US6921748B1 (en) | 1999-03-29 | 2005-07-26 | Uutech Limited | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
| US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| UA93662C2 (uk) | 2000-12-07 | 2011-03-10 | Эли Лилли Энд Компани | Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет |
| JP2005504482A (ja) | 2001-09-21 | 2005-02-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 固有の制御モジュールが無い場合の固有性の低いモジュールの使用 |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| EP1853627A2 (en) * | 2005-02-11 | 2007-11-14 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN101432025B (zh) | 2006-03-21 | 2012-04-04 | 安米林药品公司 | 肽-肽酶抑制剂结合物及其使用方法 |
| WO2010016936A1 (en) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide |
| KR20130133104A (ko) | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체 |
| BRPI0917580A2 (pt) | 2008-08-07 | 2016-10-11 | Ipsen Pharma Sas | composto, composição farmacêutica, métodos para elicitar um efeito agonista e antagonista de um receptor de gip, para tratar condições ou doenças mediadas por ligação de receptor de gip, para tratar diabetes, para tratar distúrbios relacionados com diabete, para tratar ou previnir causas secundárias de diabete para tratar obesidade, e para estimular secreção de insulina, e, uso de um análogo de peptídeo |
| EP2328922A4 (en) | 2008-08-07 | 2013-01-02 | Ipsen Pharma Sas | ANALOGUE OF GLUCOSE-DEPENDING INSULINOTROPIC POLYPEPTIDE |
| CA2733005C (en) | 2008-08-07 | 2016-09-27 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| SG191252A1 (en) | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| RU2015101697A (ru) * | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| EP3189072B1 (en) * | 2014-09-05 | 2018-07-18 | University of Copenhagen | Gip peptide analogues |
| TWI705973B (zh) | 2014-10-29 | 2020-10-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ促效劑化合物及方法 |
| WO2016205488A1 (en) | 2015-06-17 | 2016-12-22 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| US10774127B2 (en) | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
| WO2018117613A1 (ko) * | 2016-12-19 | 2018-06-28 | 한미약품 주식회사 | 뇌 표적 지속성 단백질 결합체 |
| EP3569248B1 (en) | 2016-12-26 | 2023-12-06 | Kao Corporation | Gip inhibitors for improving cognitive function |
| WO2018124011A1 (ja) | 2016-12-26 | 2018-07-05 | 花王株式会社 | 運動調節機能向上剤 |
| EP3560514A4 (en) | 2016-12-26 | 2020-12-23 | Kao Corporation | Hypothermic drugs |
| BR112019025195A8 (pt) * | 2017-05-31 | 2020-07-07 | Univ Copenhagen | análogos do peptídeo gip de ação prolongada |
-
2019
- 2019-12-03 US US17/298,512 patent/US12297250B2/en active Active
- 2019-12-03 CN CN202511386362.3A patent/CN121449720A/zh active Pending
- 2019-12-03 EP EP19812789.6A patent/EP3891174A1/en active Pending
- 2019-12-03 SG SG11202105586YA patent/SG11202105586YA/en unknown
- 2019-12-03 WO PCT/EP2019/083506 patent/WO2020115048A1/en not_active Ceased
- 2019-12-03 BR BR112021010447-0A patent/BR112021010447A2/pt unknown
- 2019-12-03 CA CA3121043A patent/CA3121043A1/en active Pending
- 2019-12-03 KR KR1020217019677A patent/KR102906485B1/ko active Active
- 2019-12-03 KR KR1020257043349A patent/KR20260011770A/ko active Pending
- 2019-12-03 EP EP19812788.8A patent/EP3891173A1/en active Pending
- 2019-12-03 CN CN202511386365.7A patent/CN121449721A/zh active Pending
- 2019-12-03 WO PCT/EP2019/083509 patent/WO2020115049A1/en not_active Ceased
- 2019-12-03 AU AU2019391300A patent/AU2019391300B2/en active Active
- 2019-12-03 JP JP2021552785A patent/JP7605747B2/ja active Active
- 2019-12-03 MX MX2021006505A patent/MX2021006505A/es unknown
- 2019-12-03 CN CN201980090373.3A patent/CN113366014B/zh active Active
- 2019-12-03 US US17/298,444 patent/US12187773B2/en active Active
-
2021
- 2021-05-24 IL IL283385A patent/IL283385A/en unknown
-
2025
- 2025-03-31 US US19/096,393 patent/US20250376499A1/en active Pending
- 2025-09-24 AU AU2025237957A patent/AU2025237957A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7658877B2 (ja) | インクレチン類似体およびその使用 | |
| JPWO2020115048A5 (enExample) | ||
| JP7605747B2 (ja) | 修飾されたｇｉｐペプチド類似体 | |
| US11008375B2 (en) | GIP-GLP-1 dual agonist compounds and methods | |
| RU2559320C2 (ru) | Новые аналоги глюкагона | |
| JP5635529B2 (ja) | グルカゴン類似体 | |
| JP2013523619A5 (enExample) | ||
| JP2020521784A5 (enExample) | ||
| JP2012506402A5 (enExample) | ||
| JP2025172864A5 (enExample) | ||
| JP2013523618A5 (enExample) | ||
| WO2015067716A1 (en) | Glucagon-glp-1-gip triple agonist compounds | |
| EP3212218A2 (en) | Gip agonist compounds and methods | |
| JP2014504597A (ja) | アシル化グルカゴン類似体とインスリン類似体の組合せ物 | |
| CA2747197A1 (en) | Glucagon analogues | |
| AU2017348172A1 (en) | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors | |
| JP2012532898A (ja) | アシル化グルカゴン類似体 | |
| AU2014345569A1 (en) | GIP-GLP-1 dual agonist compounds and methods | |
| RU2007134155A (ru) | Glp-1 соединения с увеличенным временем полужизни | |
| CA2812951A1 (en) | Engineered polypeptides having enhanced duration of action | |
| KR20110040760A (ko) | 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제 | |
| JP2013510829A (ja) | 長時間作用型ｙ２受容体アゴニスト | |
| US20240360193A1 (en) | Polypeptide derivative with dual glp-1r and gipr targeting agonistic effect, and preparation method and use thereof | |
| CN110691788B (zh) | 长效gip肽类似物 | |
| JP2023505441A (ja) | 最適化されたｇｉｐペプチド類縁体 |